SCHEDULE 13G: Nine Ten Capital Management Discloses 7.1% Stake in iRadimed Corp

Nine Ten Capital Management, along with Nine Ten Partners LP and Russell Mollen, has disclosed a beneficial ownership of 7.1% in iRadimed Corp's common stock.

Summary

• Nine Ten Capital Management LLC, Nine Ten Partners LP, and Russell Mollen have filed a Schedule 13G, indicating beneficial ownership of 905,926 shares of iRadimed Corp's common stock.
• This aggregate amount represents 7.1% of iRadimed Corp's common stock.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• The date of the event requiring this filing was December 31, 2024.

Sentiment

Score: 5

Explanation: The document is a standard ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook. It is a factual report of a significant ownership stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes, potentially influencing market perception of the stock's stability or investor interest.
• Market: Informs the market of a new or updated substantial shareholder position, which can be a factor in trading decisions.

Key Dates

Keywords

iRadimed Corp, Nine Ten Capital Management, Nine Ten Partners LP, Russell Mollen, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Ownership Disclosure